Merged from 2 sources β review for redundancy.
The net balance between toxic burden and adaptive/detoxification capacity, rather than absolute toxin exposure. Netto toxicity emphasizes that toxicity is determined by the organism's ability to process and eliminate toxins relative to exposure levels. This concept reframes toxic stress as a dynamic equilibrium between load and clearance capacity, not a fixed threshold.
Imagine your body as a city with a waste management system. The garbage trucks (detoxification enzymes) pick up trash (toxins) from the streets (bloodstream) and take it to processing plants (liver, kidneys) for disposal. Now, if the city generates 10 tons of garbage per day and you have trucks capable of hauling 15 tons, you're fine β streets stay clean, the system hums along. That's low netto toxicity.
But what if the same 10 tons of trash arrive, but half your trucks break down because the drivers are exhausted (chronic stress), the fuel is bad (nutrient deficiencies), and the processing plant is on fire (liver inflammation)? Now you only have 6 tons of capacity. The streets overflow with garbage. Same trash load, different outcome. That's high netto toxicity.
The twist: a healthy city with 20-ton capacity can even handle a temporary surge β say 18 tons during a festival (acute toxin exposure) β because it has reserves. The struggling city collapses at 11 tons. Netto toxicity isn't about the garbage; it's about the gap between what arrives and what you can clear. Two people can eat the same meal, breathe the same air, drink the same water β one thrives, the other crashes. The difference is their metabolic infrastructure.
Netto toxicity emerges from four interacting systems:
-
Total Toxic Load β environmental (heavy metals, pesticides, air pollution), dietary (xenobiotics, AGEs, endotoxin), endogenous (metabolic byproducts like ammonia, urea, oxidative radicals)
-
Phase I Detoxification (Liver CYP450 enzymes):
- CYP1A1, CYP1A2, CYP2D6 oxidize, reduce, or hydrolyze toxins
- Generates intermediate metabolites (often MORE reactive than parent compounds)
- Requires cofactors: niacin (NAD+), riboflavin (FAD), iron-sulfur clusters
- Produces Reactive Oxygen Species (ROS) as byproduct
- Upregulated by aryl hydrocarbon receptor (AhR) activation (e.g., cruciferous vegetables, polyphenols)
-
Phase II Detoxification (Conjugation):
- Glutathione conjugation via glutathione S-transferases (GSTs) β requires glutathione (rate-limited by cysteine, glycine, glutamate availability)
- Sulfation via sulfotransferases β requires sulfur from cysteine/methionine
- Glucuronidation via UDP-glucuronosyltransferases (UGTs) β requires UDP-glucuronic acid
- Methylation via COMT, HNMT β requires SAM-e (from methionine + folate + B12)
- Acetylation via N-acetyltransferases (NATs) β requires acetyl-CoA
- Converts reactive intermediates β water-soluble conjugates for excretion
-
Elimination Pathways:
- Kidneys: filtrate conjugated metabolites β urine (GFR-dependent)
- Liver/bile: secrete lipophilic conjugates β feces (requires intact bile acids, gut motility)
- Lungs: volatile compounds (acetone, ethanol metabolites)
- Skin: eccrine sweat (heavy metals, BPA, phthalates)
-
Adaptive Reserves:
- Mitochondrial dysfunction β reduced ATP for active transport, conjugation reactions, and hepatic protein synthesis
- Heat shock proteins (HSP70, HSP90) buffer protein misfolding from toxin-induced ER stress
- Nrf2 pathway: oxidative stress β Nrf2 release from Keap1 β nuclear translocation β upregulates antioxidant genes (SOD, catalase, GSTs, GCL)
- NAD availability: limits Phase I detox, mitochondrial repair (via sirtuins), DNA repair (via PARPs)
graph TD
A[Toxin Exposure] --> B{Phase I CYP450}
B --> C["Reactive Intermediate + ROS"]
C --> D{Phase II Conjugation}
D --> E[Glutathione pathway]
D --> F[Sulfation pathway]
D --> G[Methylation pathway]
D --> H[Glucuronidation pathway]
E --> I[Water-soluble conjugate]
F --> I
G --> I
H --> I
I --> J["Elimination: Kidney, Bile, Sweat"]
K[Adaptive Capacity] --> L[Mitochondrial ATP]
K --> M[Glutathione reserves]
K --> N["NAD+ pool"]
K --> O[Nrf2 antioxidant response]
L -.->|powers| B
L -.->|powers| D
M -.->|fuels| E
N -.->|cofactor| B
O -.->|upregulates| D
P[Stressors] --> Q["β Mitochondrial function"]
P --> R["β Glutathione synthesis"]
P --> S["β Methylation capacity"]
Q --> T["β Netto Toxicity"]
R --> T
S --> T
C --> T
Netto Toxicity Formula (conceptual):
Netto Toxicity = Toxic Load β (Phase I + Phase II + Elimination + Adaptive Reserve)
When adaptive reserves are depleted (chronic stress, sleep deprivation, inflammation, nutrient deficiencies), the same toxic load overwhelms the system β accumulation β oxidative damage β mitochondrial dysfunction β further reduced detox capacity (vicious cycle).
cPNI Reframe: Stop asking "Is this toxin safe?" Start asking "Can this patient's system handle their current load?"
Clinical Scenarios:
- Chronic Fatigue/Fibromyalgia: Often exhibit glutathione depletion (<800 ΞΌmol/L), elevated lipid peroxides, low urinary sulfate (impaired Phase II). Same dietary/environmental exposure as healthy controls, but netto toxicity is high due to mitochondrial/detox dysfunction.
- Autoimmune Conditions: chronic inflammation depletes cysteine (shunted to acute phase proteins), reduces glutathione synthesis β impaired conjugation of xenobiotics β accumulation of immunogenic haptens (e.g., heavy metals bind self-proteins β neoantigens).
- MCS (Multiple Chemical Sensitivity): Polymorphisms in GSTM1, GSTT1 (null genotypes = no enzyme activity) + chronic oxidative stress β catastrophic loss of Phase II capacity β reactivity to low-dose exposures.
- Depression/Anxiety: chronic inflammation (IL-6 >3 pg/mL) diverts tryptophan to kynurenic acid (neurotoxic) rather than serotonin; methylation deficits impair dopamine/norepinephrine clearance β dysregulated neurotransmission.
Metamodel Connections:
- Metamodel 1 (Intermittent Living): Hormesis improves netto toxicity β fasting upregulates autophagy (clears damaged proteins), cold exposure induces Nrf2 (antioxidant genes), exercise transiently increases ROS β adaptive upregulation of detox enzymes.
- Selfish Brain: Brain prioritizes glucose/energy β under metabolic stress, peripheral detox capacity is sacrificed (liver ATP diverted to gluconeogenesis).
- Evolutionary mismatch: Hunter-gatherers had high physical activity (induces mitochondrial biogenesis, heat shock response), seasonal variation (intermittent toxin exposure with recovery periods), phytonutrient-dense diet (polyphenols activate Nrf2). Modern life: constant low-grade exposure + sedentarism + processed food = chronic depletion of adaptive reserves.
Intervention Strategy:
- Reduce Load (but don't obsess): filter water, organic where feasible, avoid obvious toxins (smoking, excess alcohol)
- Enhance Capacity (primary focus):
- Support glutathione: NAC 600-1200 mg/day, glycine 3-5 g/day, selenium 200 ΞΌg/day, whey protein (cysteine source)
- Support methylation: methylfolate 400-800 ΞΌg, methylcobalamin 1000 ΞΌg, betaine/TMG 500-1000 mg
- Upregulate Nrf2: sulforaphane (broccoli sprouts), curcumin, green tea EGCG, resveratrol
- Mitochondrial support: CoQ10 100-300 mg, magnesium glycinate 400 mg, B-complex
- Enhance elimination: adequate hydration (urine specific gravity <1.015), fiber 30-40 g/day (bile acid binding), sauna 2-3x/week (sweat toxin excretion)
- Build Adaptive Reserve: prioritize sleep (NAD+ regeneration, autophagy), manage stress (cortisol depletes glutathione), physical activity (mitochondrial biogenesis)
Exam-Relevant Insight: A patient with perfect diet avoiding all toxins but chronic insomnia, high stress, and sedentary lifestyle will have HIGHER netto toxicity than someone eating occasional junk food but sleeping 8 hours, exercising daily, and managing stress. Detoxification is a metabolic CAPACITY, not a binary "cleanse."
- Netto toxicity = toxic load β detoxification capacity β adaptive reserves
- Glutathione is the rate-limiting conjugation molecule for Phase II detox; synthesized from cysteine (rate-limiting), glycine, and glutamate via GCL and GS enzymes
- Phase I CYP450 enzymes often generate MORE toxic intermediates (e.g., acetaldehyde from alcohol, quinones from benzene) β Phase II must conjugate them rapidly
- GSTM1 and GSTT1 null genotypes (present in ~50% of populations) = zero enzyme activity β 2-5Γ higher cancer/toxicity risk with same exposures
- Chronic stress depletes glutathione via cortisol-induced cysteine shunting to cortisol synthesis and acute phase proteins
- Sleep deprivation reduces NAD+ regeneration (required for CYP450 function) and impairs glymphatic clearance (brain detox pathway)
- Nrf2 activation (via sulforaphane, curcumin, exercise) can increase detox enzyme expression 200-500% within 24-48 hours
- Urinary sulfate:creatinine ratio <1.0 suggests impaired sulfation capacity (requires cysteine/methionine intake)
- Sauna therapy (60-80Β°C, 15-30 min, 3x/week) increases urinary/sweat excretion of heavy metals (lead, cadmium, mercury) by 10-15%
- Mitochondrial dysfunction (low ATP) impairs bile secretion β toxin reabsorption via enterohepatic circulation β increased systemic load
- Same toxin exposure (e.g., 10 ΞΌg/dL blood lead) associated with no symptoms in one person, severe fatigue/cognitive impairment in another due to glutathione/methylation status
- Hormesis β Low-dose stressors (exercise, fasting, cold, phytonutrients) activate Nrf2/HSP/autophagy pathways, enhancing detoxification capacity and reducing netto toxicity
- Glutathione synthesis β Rate-limiting step for Phase II conjugation; requires cysteine (from diet/transsulfuration), glycine, glutamate, and ATP β depletion increases netto toxicity
- Mitochondrial dysfunction β Reduced ATP production impairs active detox processes (CYP450, conjugation, bile secretion, renal clearance) and increases oxidative stress from impaired ETC function
- Low-grade inflammation β Chronic IL-6/TNF-Ξ± diverts cysteine to acute phase protein synthesis, depletes glutathione, induces mitochondrial dysfunction β catastrophic reduction in detox capacity
- Liver detoxification β Phase I (CYP450) and Phase II (conjugation) determine clearance capacity; liver inflammation/fibrosis reduces enzyme expression and biliary excretion
- Methylation β COMT, HNMT, NNMT conjugate catecholamines, histamine, nicotinamide via SAM-e; deficits (MTHFR polymorphisms, B12/folate deficiency) impair detox and increase netto toxicity
- NAD β Cofactor for Phase I CYP450 enzymes, sirtuins (mitochondrial repair), PARPs (DNA repair); depletion (chronic stress, poor sleep, NAD-consuming infections) reduces detox capacity
- Nrf2 pathway β Master regulator of antioxidant/detox gene expression (SOD, catalase, GSTs, GCL, HO-1); activated by ROS, electrophiles, phytonutrients β upregulation reduces netto toxicity
- Chronic stress β Elevates cortisol β cysteine depletion (shunted to cortisol/acute phase synthesis) β reduced glutathione β impaired Phase II β increased netto toxicity
- Sleep β Essential for NAD+ regeneration (CYP450 cofactor), autophagy (cellular cleanup), glymphatic clearance (brain detox), mitochondrial repair β deprivation increases netto toxicity
- Microbiome β Gut bacteria produce Ξ²-glucuronidase (deconjugates Phase II metabolites β reabsorption), regulate bile acid metabolism, synthesize short-chain fatty acids (support gut barrier integrity preventing endotoxin load)
- Gut permeability β Increased LPS translocation triggers systemic inflammation β depletes glutathione, impairs hepatic detox, increases metabolic endotoxin burden (endogenous toxic load)
- Diet β Cruciferous vegetables (sulforaphane β Nrf2), alliums (organosulfurs β glutathione precursors), green tea (EGCG β Nrf2), whey protein (cysteine), fiber (bile acid binding/excretion)
- Physical activity β Induces transient ROS β hormetic upregulation of Nrf2/SOD/catalase, increases mitochondrial biogenesis, enhances hepatic blood flow (toxin clearance), stimulates lymphatic drainage
- Inflammation-associated anorexia β Cytokine-induced appetite suppression reduces protein intake β cysteine/glycine deficiency β glutathione depletion β reduced detox capacity during acute illness (evolutionary trade-off)
- Oxidative Stress β Overwhelms antioxidant systems (SOD, catalase, glutathione peroxidase) when netto toxicity high β lipid peroxidation, DNA damage, protein carbonylation β mitochondrial dysfunction (vicious cycle)
- CYP450 β Polymorphisms (e.g., CYP2D6 poor metabolizers = 7% Europeans) dramatically alter Phase I capacity; some accelerate detox (ultra-rapid), others impair it (poor metabolizers) β genetic variance in netto toxicity
- Heavy metals β Lead, mercury, cadmium deplete glutathione (form mercaptide conjugates), inhibit mitochondrial enzymes (ETC complexes), generate ROS β exponential increase in netto toxicity with chronic exposure
- Polyphenols β Activate Nrf2 (upregulate Phase II enzymes), chelate metals, scavenge free radicals, support gut barrier (reduce endotoxin load) β reduce netto toxicity via multiple pathways
- Autophagy β Cellular "cleanup" process activated by fasting, exercise, sleep β degrades damaged proteins/organelles, recycles amino acids (including cysteine for glutathione synthesis), removes toxin-bound structures
- Bile acids β Secreted by liver to excrete lipophilic toxins; reabsorbed in ileum (enterohepatic circulation); dysbiosis-induced Ξ²-glucuronidase deconjugates bile-bound toxins β reabsorption β increased netto toxicity
- Resilience β Metabolic resilience determines netto toxicity tolerance; high mitochondrial density, robust glutathione synthesis, efficient methylation, low inflammation = low netto toxicity despite exposures
Netto toxicity is the effective toxic burden on an organism after accounting for detoxification capacity, elimination efficiency, and compensatory mechanisms. It represents the algebraic sum of toxic exposure minus the organism's ability to neutralize, conjugate, sequester, and excrete harmful substances. Unlike absolute exposure metrics, netto toxicity reflects functional impact β two individuals with identical exposures may have vastly different netto toxicities based on genetic polymorphisms, nutritional status, organ function, and adaptive capacity.
Imagine a city's waste management system. Garbage trucks (toxins) arrive constantly β some from outside (pollution, diet), some generated internally (metabolic byproducts). The city has a waste processing plant with three zones: Zone 1 breaks down trash into smaller pieces (CYP450 Phase I), Zone 2 packages it for safe transport (Phase II conjugation with glutathione, sulfate, glucuronic acid), and Zone 3 ships it out via trucks and rivers (Liver bile, kidney urine). The city also has emergency storage β vacant lots where trash can be temporarily dumped (adipose tissue sequestration). Netto toxicity is what happens when garbage trucks arrive faster than the plant can process them, or when the plant workers are understaffed (nutrient deficiencies), the machinery is broken (genetic variants like MTHFR), or the rivers are clogged (kidney/liver disease). A well-run city handles constant moderate input without crisis. But flood the system or sabotage the plant, and garbage piles up in the streets β that's when symptoms appear. Two cities with the same garbage input can have completely different outcomes depending on their processing infrastructure.
Detoxification occurs in three coordinated phases, each with specific molecular machinery and rate-limiting factors:
Phase I (Functionalization)
Cytochrome P450 enzymes (CYP1A1, CYP1A2, CYP2D6, CYP2E1, CYP3A4) catalyze oxidation, reduction, or hydrolysis reactions, introducing or exposing reactive groups (-OH, -SH, -NH2) on lipophilic compounds. This is the rate-limiting step for many xenobiotics. CYP activity is genetically variable β poor metabolizers (CYP2D6 *4/*4) accumulate parent compounds, while ultra-rapid metabolizers may generate excess reactive intermediates. Phase I reactions often increase reactivity, producing Reactive Oxygen Species and electrophilic intermediates that can damage DNA and proteins if Phase II is insufficient.
Phase II (Conjugation)
High-energy donor molecules attach to Phase I products, rendering them water-soluble and excretable:
- Glutathione conjugation (via glutathione S-transferases): neutralizes electrophiles and free radicals. Glutathione availability is rate-limiting; synthesis requires cysteine, glycine, glutamate, and ATP. GCLM polymorphisms reduce synthesis capacity.
- Glucuronidation (via UDP-glucuronosyltransferases): conjugates with UDP-glucuronic acid. Requires adequate UDP-glucose and NAD+.
- Sulfation (via sulfotransferases): uses PAPS (3'-phosphoadenosine-5'-phosphosulfate) as sulfur donor. Limited by sulfur-containing amino acids (methionine, cysteine).
- Methylation (via methyltransferases): uses SAM-e (S-adenosylmethionine) as methyl donor. MTHFR C677T variant reduces 5-MTHF production, impairing methylation capacity by ~30-40%. Methylation detoxifies heavy metals (arsenic, mercury), catecholamines, and homocysteine.
- Acetylation (via N-acetyltransferases): fast/slow acetylator phenotypes determined by NAT1/NAT2 polymorphisms.
Phase III (Elimination)
Membrane transporters (P-glycoprotein, multidrug resistance proteins, organic anion transporters) actively export conjugated toxins from cells into bile (via Liver canaliculi) or urine (via kidney proximal tubules). The gut microbiome influences this phase via beta-glucuronidase enzymes that can deconjugate compounds in the colon, enabling reabsorption (enterohepatic recirculation) and increasing netto toxicity.
Compensatory Mechanisms
- Adipose sequestration: Lipophilic toxins (PCBs, dioxins, heavy metals bound to lipoproteins) partition into adipose tissue, reducing circulating levels but creating long-term storage. Rapid fat loss (fasting, illness) can mobilize stored toxins, causing acute toxicity.
- Antioxidant buffering: SOD, catalase, glutathione peroxidase neutralize ROS generated during Phase I. Activity depends on Selenium, Zinc, manganese, and glutathione availability.
- Heat shock proteins: HSP 70/90 stabilize damaged proteins, preventing aggregation.
- Hormetic upregulation: Mild toxin exposure (e.g., Nrf2 activators like sulforaphane) induces Phase II enzyme expression, increasing capacity.
graph TD
A[Toxic Exposure] --> B["Phase I: CYP450 Oxidation"]
B --> C[Reactive Intermediates]
C --> D["Phase II: Conjugation"]
D --> E[Glutathione]
D --> F[Glucuronidation]
D --> G[Sulfation]
D --> H[Methylation via SAM-e]
E --> I["Phase III: Membrane Transport"]
F --> I
G --> I
H --> I
I --> J[Bile Excretion]
I --> K[Urine Excretion]
C --> L[Oxidative Stress if Phase II Saturated]
L --> M[DNA/Protein Damage]
A --> N[Adipose Sequestration]
N --> O[Long-term Storage]
O --> P[Mobilization during Fat Loss]
P --> B
D --> Q{Nutrient/Genetic Capacity}
Q -->|MTHFR variant| R[Reduced Methylation]
Q -->|Glutathione depletion| S[Reduced Conjugation]
R --> L
S --> L
Netto toxicity is central to understanding why identical exposures produce different clinical outcomes. In cPNI practice, assessment must evaluate both exposure burden and detoxification capacity:
Patient Groups at High Risk
- Genetic variants: MTHFR C677T/A1298C (impaired methylation), GSTM1 null (reduced glutathione conjugation), CYP2D6 poor metabolizers (drug accumulation), COMT Val158Met (altered catecholamine clearance).
- Nutrient deficiencies: B vitamins (B2, B6, B9, B12 for methylation), glutathione precursors (cysteine, glycine, NAC), sulfur amino acids (methionine, cysteine), Selenium (glutathione peroxidase cofactor), Magnesium (hundreds of enzymatic reactions).
- Organ dysfunction: Liver disease (reduced CYP activity, impaired bile production), Chronic Kidney Disease (reduced urinary excretion, fluid retention), gut dysbiosis (increased beta-glucuronidase activity, heightened Endotoxemia).
- High exposure burden: environmental toxins (air pollution, pesticides, heavy metals), alcohol, medications with high hepatic metabolism, chronic infections producing endotoxins.
Metamodel Connections
This concept bridges Metamodel 1 (compensation and adaptation) and the Selfish Brain / selfish immune system frameworks. The brain and immune system compete for detoxification resources β inflammation increases glutathione consumption (immune cells use it for respiratory burst), potentially depleting brain antioxidant capacity. Chronic stress elevates Cortisol, which induces CYP3A4 (altering drug metabolism) but suppresses Phase II enzymes. Insulin resistance impairs hepatic detoxification by diverting metabolic resources toward glucose handling.
Clinical Thresholds and Biomarkers
- Glutathione: Erythrocyte GSH:GSSG ratio <10:1 indicates oxidative stress. Urinary 8-OHdG >15 ng/mg creatinine suggests DNA oxidative damage.
- Methylation: Plasma Homocysteine >10 ΞΌmol/L indicates impaired methylation (target <7 ΞΌmol/L). SAM-e:SAH ratio <4:1 signals methylation insufficiency.
- Liver function: AST/ALT >2 suggests alcoholic liver disease; <1 typical of NAFLD. GGT >30 U/L indicates Phase II stress or alcohol exposure.
- Kidney function: eGFR <60 mL/min/1.73mΒ² (Stage 3 CKD) significantly impairs toxin clearance.
- Oxidative stress: hsCRP >3 mg/L, F2-isoprostanes >160 pg/mg creatinine.
Intervention Implications
- Reduce exposure: Prioritize avoidable sources (clean water, organic food, air filtration) over obsessive avoidance.
- Support Phase I: Moderate, not excessive (high Phase I with low Phase II increases toxicity). Cruciferous vegetables induce CYP1A2 safely.
- Optimize Phase II:
- Glutathione: NAC 600-1800 mg/day, whey protein (rich in cysteine), glycine 3-5 g/day.
- Methylation: 5-MTHF 400-1000 ΞΌg, B12 (methylcobalamin) 1000 ΞΌg, B6 (P5P) 50 mg, betaine (trimethylglycine) 500-3000 mg.
- Sulfation: MSM, taurine, epsom salt baths (magnesium sulfate).
- Enhance Phase III: Adequate hydration (30-40 mL/kg/day), fiber (25-35 g/day to bind toxins in gut), Bile acids support (taurine, choline).
- Restore organ function: Hepatoprotective herbs (Silybum marianum, Curcuma), kidney support (adequate hydration, BP control), gut microbiome restoration (probiotics, prebiotics, Faecalibacterium prausnitzii).
- Hormetic strategies: Intermittent fasting (upregulates autophagy), Exercise (induces Nrf2), sauna (induces heat shock proteins).
Evolutionary Mismatch
Modern humans face unprecedented xenobiotic exposure (>80,000 synthetic chemicals since 1950) without corresponding genetic adaptation. Our detoxification systems evolved for plant toxins, microbial byproducts, and occasional carrion consumption β not persistent organic pollutants, pharmaceutical polypharmacy, or industrial solvents. This mismatch creates chronic low-grade toxicity in populations with average detoxification capacity, while genetic variants that were neutral in ancestral environments (e.g., slow acetylators) become disease risks.
- Netto toxicity = exposure load β (Phase I + Phase II + Phase III + sequestration) capacity
- MTHFR C677T homozygotes (TT) have ~70% of normal enzyme activity; C677T/A1298C compound heterozygotes ~50%
- GSTM1 null genotype (50% of Caucasians) eliminates one glutathione conjugation pathway
- Glutathione depletion <1 mM in hepatocytes shifts metabolism from conjugation to oxidative damage
- Phase I without adequate Phase II increases toxicity by generating reactive intermediates (e.g., paracetamol toxicity)
- Adipose tissue can store lipophilic toxins for years; rapid weight loss mobilizes them faster than detox systems can process
- Gut microbiome beta-glucuronidase increases estrogen, bilirubin, and xenobiotic reabsorption by 20-40%
- Chronic alcohol (>2 drinks/day) induces CYP2E1, increasing acetaminophen toxicity risk
- SAM-e levels drop 50% in B12 deficiency, impairing methylation of heavy metals, neurotransmitters, and DNA
- Selenium deficiency (<70 ΞΌg/L serum) reduces glutathione peroxidase activity by 40-60%, increasing oxidative damage
- Cytochrome P450 β Phase I enzymes that initiate detoxification but can generate toxic intermediates
- Glutathione β Rate-limiting Phase II conjugator; depletion shifts netto toxicity positive
- MTHFR β Genetic variant impairing methylation-dependent detoxification pathways
- Liver β Primary detoxification organ housing 90% of Phase I/II enzymes
- gut microbiome β Modulates toxin metabolism via beta-glucuronidase and direct xenobiotic transformation
- Methylation β Essential Phase II pathway for heavy metals, catecholamines, and homocysteine
- Oxidative Stress β Consequence of netto toxicity exceeding antioxidant buffering capacity
- inflammation β Both driver (increases toxin production) and consequence (damage from uncleared toxins) of netto toxicity
- Netto Symptoms β Parallel concept: apparent symptoms depend on compensation minus stressor load
- B vitamins β Cofactors for Phase II enzymes (B2, B6) and methylation donors (folate, B12)
- environmental toxins β External exposure component of total toxic burden equation
- Endotoxemia β Endogenous toxin source (LPS from gut dysbiosis) contributing to netto toxicity
- Chronic Kidney Disease β Impairs Phase III excretion, elevating netto toxicity at same exposure
- adipose tissue β Sequesters lipophilic toxins, creating time-delayed toxicity during fat mobilization
- antioxidant systems β SOD, catalase, glutathione peroxidase buffer Phase I-generated ROS
- single nucleotide polymorphisms β Genetic variation in CYP, GST, NAT, MTHFR determines individual detox capacity
- Metabolic flexibility β Metabolically healthy individuals better allocate resources to detoxification
- Insulin resistance β Diverts hepatic resources from detoxification to gluconeogenesis, raising netto toxicity
- SAM-e β Universal methyl donor for Phase II methylation; depleted in B12/folate deficiency
- NAC β Glutathione precursor that directly supports Phase II conjugation capacity
- Selenium β Cofactor for glutathione peroxidase; deficiency impairs antioxidant defense
- Nrf2 β Master regulator of Phase II enzyme expression; activated by Hormesis
- Bile acids β Phase III excretion route; recycling via enterohepatic circulation affects netto toxicity
- COMT β Methylates catecholamines; Val158Met variant slows clearance, increasing oxidative stress
- CYP2D6 β Highly polymorphic CYP enzyme; poor metabolizers accumulate tricyclics, SSRIs, codeine
- gut barrier function β Impaired barrier increases endotoxin load, adding to netto toxicity
- Chronic stress β Elevates cortisol, inducing CYP3A4 but suppressing Phase II, unbalancing detoxification